Abstract
Background: Adiponectin (APN), which was secreted from adipose tissue, was extensively investigated in various diseases such as obesity as well as obesity-related cancers.
Method: Here, we investigated serum adiponectin level in gastric cancer (GC) patients and healthy control subjects using a well-established N-succinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate (SMCC) modified protein biochip. Results: We found that serum adiponectin level significantly decreased in the patients with GC when compared with the controls (p<0.01). Women had higher adiponectin level than men in the controls (p=0.024), but no gender difference occurred in the GC patients (p>0.05). Correlation analysis between serum adiponectin expression and clinicopathological characteristics in the GC patients indicated that serum adiponectin level was obviously correlated with tumor location (p=0.008), differentiated degree (p=0.011) and histologic type (p=0.006). Conclusion: Our results revealed that serum adiponectin might potentially reflect location, histogenesis and differentiation of GC. The biochip immunoassay would act as one substitute of conventional clinical assays for measuring serum adiponectin in GC.Keywords: Adiponectin (APN), biochip, gastric cancer (GC), immunoassay, N-succinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate (SMCC), serum.
Graphical Abstract
Related Journals
Related Books
Industrial Applications of Soil Microbes
Industrial Applications of Soil Microbes
Algal Biotechnology for Fuel Applications
Biopolymers Towards Green and Sustainable Development
Terpenoids: Recent Advances in Extraction, Biochemistry and Biotechnology
Environmental Microbiology: Advanced Research and Multidisciplinary Applications
Biomarkers in Medicine
Industrial Applications of Soil Microbes
Recent Advances in Biotechnology
Sustainable Utilization of Fungi in Agriculture and Industry
22
2
1